Five theses on the Delta-Dossier: Why Germany needs more than cross-references

The term Delta-Dossier is not an official regulatory term. In the German market-access context, it describes the national adaptation required to use content from the European JCA dossier in the AMNOG process and to supplement it with Germany-specific content, analyses and evidence.

With tovorafenib/OJEMDA, the first practical test of this interface is now available. The G-BA benefit assessment published on 17 August 2026 shows how content from a JCA dossier is reused in a real German AMNOG dossier and where the national assessment applies its own requirements.

What happens after a JCA in the German AMNOG process?

Following a Joint Clinical Assessment, the German early benefit assessment remains a separate national procedure. The JCA dossier and JCA report can be relevant where their content addresses the German assessment question. National requirements for populations, appropriate comparator therapy, patient-relevant endpoints, methods, subgroups and evidence updates nevertheless remain in place.

The Delta-Dossier addresses this interface. It identifies which European content can be used or specifically referenced for Germany and where selection, adaptation, additional analyses or new national content are required.

JCA dossier, JCA report, AMNOG dossier and Delta-Dossier compared

The distinction is also relevant procedurally. For tovorafenib, the JCA dossier was among the documents used in the German benefit assessment. The final JCA report had not yet been published when the German procedure started and could therefore not be considered in the assessment published on 17 August 2026.

The five theses on the Delta-Dossier at a glance

The Delta-Dossier translates European JCA evidence into the requirements of the German AMNOG process. Five interfaces are particularly relevant: the assessment question, PICO and comparator, endpoints and methods, national additions, and evidence updates and timing.

Thesis 1: EU HTA does not replace the national assessment in Germany

The Joint Clinical Assessment does not replace the German early benefit assessment. The European assessment provides clinical evidence against the European assessment scope, while the national assessment of added benefit remains part of AMNOG.

Tovorafenib confirms this distinction. Because the medicine has orphan-drug status, its medical added benefit is considered proven by virtue of marketing authorisation in Germany; the G-BA procedure assesses its extent. The JCA, by contrast, addressed relative clinical effectiveness and safety across eight PICO questions.

Thesis 2: The Delta-Dossier is a translation task

References to the JCA dossier can make national dossier development more efficient, but they do not replace an assessment of whether the content meets German requirements. Specific references are possible; broad or dynamic references are not sufficient. The national AMNOG modules remain in place and there is no separate regulatory Delta-Dossier template.

The work consists of four tasks: reuse suitable content, selection of relevant PICOs and results, adaptation of content or analyses, and addition of Germany-specific content, updates or analyses.

The first practical test shows that Module 3 remains strongly national: epidemiology, the German statutory health insurance target population, healthcare context and costs require Germany-specific preparation. Module 4 offers greater scope for reuse, including study characteristics, methodology, operationalisation and results.

Thesis 3: The real work starts long before the Delta-Dossier

National applicability is determined to a considerable extent before the Delta-Dossier is written. PICO scoping, comparator strategy, study design and evidence planning determine which European questions can later be answered with robust evidence.

The tovorafenib assessment scope covered three populations and eight PICO questions. No usable comparative results were available for six of the eight questions. The case also shows why individualised treatment comparators, external evidence and indirect comparisons need to be considered early. An evidence gap that exists at JCA stage cannot be solved by the later dossier structure alone.

Thesis 4: The greatest risks lie in comparators, endpoints and methods

Whether European evidence is suitable for Germany depends particularly on the comparator, patient relevance of endpoints and methodological usability. A European comparator and the appropriate comparator therapy specified by the G-BA do not necessarily coincide.

For PICO 5, the JCA presented an unanchored Matching-Adjusted Indirect Comparison between tovorafenib and dabrafenib plus trametinib. The JCA described substantial uncertainty, including possible residual confounding and small effective sample sizes. The G-BA did not use the MAIC for the German assessment.

PFS and objective response were included in the European scope but were not considered suitable patient-relevant efficacy endpoints in the submitted operationalisations. Reuse does not replace national quality assessment: population, endpoint, operationalisation, analysis population and statistical method must still be assessed against German requirements.

Thesis 5: Timing and evidence updates become critical success factors

JCA and AMNOG may operate with different evidence bases and publication timelines. The Delta-Dossier therefore needs to account for evidence updates and the availability of the final JCA report.

The JCA used the two-year FIREFLY-1 data cut, while the German dossier included a newer three-year data cut. The G-BA used the three-year cut of 6 June 2025 because it provided the longest follow-up. The national evidence base therefore need not be identical to the JCA evidence base.

Preparation should answer three questions: What evidence cut-off underpins the JCA dossier? What new evidence will be available before the German procedure starts? When will the final JCA report be available relative to AMNOG?

From the JCA to the G-BA resolution

The first practical test confirms the five interfaces

Tovorafenib is a single orphan-drug procedure and not a blueprint for all future Delta-Dossiers. It nevertheless provides observations across all five theses: separate national assessment, selective evidence transfer, early evidence gaps, national methodological review, and different evidence and publication timelines.